Hypothesis was proposed based on the results of in vitro and in vivo experiments: Berberine represses Wnt/β-catenin pathway activation via modulating the miR-103a-3p/Bromodomain-containing protein 4 (BRD4) axis, thereby refraining pyroptosis and reducing the intestinal mucosal barrier defect induced via colitis. The gene discussed is BRD4; the disease is colitis.